We are live on ! Find out more
XPH icon

State Street SPDR S&P Pharmaceuticals ETF

71 hedge funds and large institutions have $129M invested in State Street SPDR S&P Pharmaceuticals ETF in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

168% more capital inflows, than outflows

Capital inflows: $41.9M | Capital outflows: $15.6M

11.79% more ownership

Funds ownership: 63.5% → 75.29% (+12%)

3% less funds holding

Funds holding: 73 → 71 (-2)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

22% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 23

50% less call options, than puts

Call options by funds: $569K | Put options by funds: $1.14M

Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
18
Reduced
23
Closed
9
Calls
$569​K
Puts
$1.14​M
Net Calls
-⁠$574​K
Net Calls Change
+$303​K

XPH Hedge Fund Activity: Q1 2025 in Review

71 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2025, worth a combined $129M — up 27% from $101M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of XPH and 8 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 18 added.

The largest buyer was Bank of America, adding an estimated $19.6M. The largest seller was Morgan Stanley, cutting an estimated $5.05M.

  • 71 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2025, down from 73 in Q4 2024.
  • Funds reported $129M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2025, up 27% quarter-over-quarter.
  • 8 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2025 and 9 closed out, a net change of -1 holder.
  • The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2025 was Bank of America, an estimated $19.6M added.
  • The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2025 was Morgan Stanley, an estimated $5.05M sold.

Based on aggregated 13F filings for Q1 2025.